ARCHIVES

Brigham & Women’s Suspends Controversial Morcellation Study As Apparent “Difference of Opinion” with FDA Comes to Light

This article is from The Cancer Letter archive.

Vol. 40 No. Nov 26 special report | November 26, 2014

Download PDF Visit The Full Archive

Related Articles

Arzerra Maintenance Therapy Extends PFS In Phase III Trial, Compared to Observation

August 29, 2014

Sponsors Withdraw Indications for Iressa, Celebrex

February 11, 2011

Radiation, Tamoxifen After Surgery Reduce Breast Cancer Occurrence

March 25, 2011

House Subcommittee Adds $30 Billion to NCI ’79 Budget

May 12, 1978

DCT Board Sends Message On Cutting Grants to Extend Paylines, Then Tries To Take It Back

March 2, 1984

Women’s Health: Treatment to Move Toward Pre-Cancer, Klausner Says

December 5, 1997